OriGen Biomedical, Inc.

Austin, Texas

Classification

Private

About

About

OriGen Biomedical, Inc. is a medical device company founded in 1997 by Richard Martin, with its headquarters located in Austin, Texas. The company specializes in developing and manufacturing products for cryopreservation and cell culture, primarily serving the medical and biotechnology sectors. OriGen Biomedical focuses on creating high-quality solutions to support patient health, particularly in areas such as cell therapy and regenerative medicine. Business/Product Breakdown OriGen Biomedical, Inc. designs and manufactures a range of cryopreservation and cell culture products tailored for applications in cell therapy, regenerative medicine, and bioprocessing. Its cryopreservation portfolio includes specialized bags and containers for the storage and transport of biological materials at ultra-low temperatures, ensuring the viability of cells and tissues. The company also offers cell culture products, such as permeable support systems and accessories, to facilitate the growth and maintenance of cells in controlled environments. All products are developed with a focus on quality, adhering to ISO 13485 and Medical Device Single Audit Program (MDSAP) certifications, and are subject to regular audits to meet regulatory and customer standards. OriGen's solutions are used by healthcare providers, research institutions, and biotechnology companies to advance patient care and therapeutic outcomes.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private